NEW YORK, July 9 - Biotique Systems today said it has licensed its BLIS data-integration platform to Bristol-Myers Squibb.
The deal, sealed at the end of the last quarter, covers five BMS sites with some 2,000 employees, Biotique said. With the technology, BMS will be able to marry public genomic data with its in-house data.
Biotique, which counts as competitors Lion Bioscience and Compugen, has also licensed the BLIS platform to Berlex Biosciences.
Click here for more information.